Why Invest?

  • Patented CardioVere technology leverages proven VeroVision┬« platform
  • Clinical feasibility established through human clinical trial
  • Value to patients, clinicians, health systems/hospitals, payers
  • Series A: 2.8X MOIC (Multiple on Invested Capital)

Addresses Significant Unmet Market Need

CHF info

Product Launch in 3 Years

Technical feasibility confirmed in human clinical studies

Built on proven ChemImage VeroVision technology platform

Intellectual property
includes 28 patents

Uses light to non-invasively measure edema

  • Current standard of care at home is daily weight which is not adequate measure of edema change
  • Current standard of care in clinical setting is pitting edema test which can be subjective

Patients take control of health to reduce readmissions

  • Patients monitor their edema post-discharge
  • Quantitative edema level monitoring
  • Similar to home blood glucose monitoring

Product Status

CardioVere is currently in the design phase of the product lifecycle and we are actively seeking investors to fund early stage development and business operations.

Clinical studies ongoing

  • Endpoint 1: Differentiation of edema vs. normal patients - complete
  • Endpoint 2: Development of CardioVerification Index - in process

Next Steps

Design & Development
  • Obtain Series A funding
  • Market research and voice of customer to determine market requirements
  • Product design and development
  • Production of engineering units
  • Refine algorithms and software
  • End user testing and optimization
  • Validate regulatory and clinical strategy and conduct initial regulatory discussions
Final Commercial Design

with DHF, Clinical Trials, de novo
Regulatory Submission

Commercialization and
Launch into Clinical Setting
Commercialization and
Launch into Home Setting

Invest Today